Developing therapeutics solutions for severe infectious diseases with unmet need
Anviro Therapeutics (“Anviro”) is an early-stage biopharmaceutical company engaged in the development of novel therapeutics for infectious diseases. Our primary areas of focus is on the validation of a small molecule called KPB-100 as a treatment for acyclovir-resistant human herpes virus.
Our Focus
Treatment Resistant Human Herpes Virus